Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Bipolar Disorder | 111 | 2023 | 376 | 16.150 |
Why?
|
Impulsive Behavior | 50 | 2022 | 142 | 9.460 |
Why?
|
Depressive Disorder | 37 | 2021 | 557 | 3.330 |
Why?
|
Antisocial Personality Disorder | 13 | 2016 | 62 | 3.310 |
Why?
|
Substance-Related Disorders | 24 | 2024 | 524 | 3.060 |
Why?
|
Depressive Disorder, Major | 13 | 2022 | 441 | 2.820 |
Why?
|
Suicide | 10 | 2023 | 180 | 2.530 |
Why?
|
Evoked Potentials, Auditory | 8 | 2016 | 50 | 2.450 |
Why?
|
Attention | 9 | 2019 | 281 | 2.410 |
Why?
|
Psychiatric Status Rating Scales | 66 | 2019 | 901 | 2.120 |
Why?
|
Disruptive, Impulse Control, and Conduct Disorders | 10 | 2009 | 33 | 2.030 |
Why?
|
Suicide, Attempted | 16 | 2020 | 129 | 1.980 |
Why?
|
Valproic Acid | 29 | 2008 | 263 | 1.920 |
Why?
|
Aggression | 20 | 2014 | 252 | 1.820 |
Why?
|
Methylphenidate | 28 | 2010 | 103 | 1.700 |
Why?
|
Lithium | 25 | 2006 | 71 | 1.700 |
Why?
|
Sensory Gating | 4 | 2013 | 14 | 1.600 |
Why?
|
Reward | 10 | 2021 | 169 | 1.510 |
Why?
|
Central Nervous System Stimulants | 27 | 2010 | 225 | 1.510 |
Why?
|
Norepinephrine | 19 | 2013 | 272 | 1.380 |
Why?
|
Antimanic Agents | 13 | 2008 | 39 | 1.360 |
Why?
|
Motor Activity | 34 | 2010 | 693 | 1.270 |
Why?
|
Antidepressive Agents | 15 | 2023 | 332 | 1.260 |
Why?
|
Reaction Time | 13 | 2014 | 234 | 1.140 |
Why?
|
Memory, Short-Term | 6 | 2011 | 160 | 1.100 |
Why?
|
Antipsychotic Agents | 19 | 2017 | 414 | 1.100 |
Why?
|
Ketamine | 7 | 2023 | 234 | 1.080 |
Why?
|
Anxiety | 9 | 2019 | 1179 | 0.980 |
Why?
|
Cocaine-Related Disorders | 10 | 2010 | 231 | 0.890 |
Why?
|
Mental Disorders | 10 | 2022 | 862 | 0.870 |
Why?
|
Affect | 8 | 2017 | 288 | 0.840 |
Why?
|
Anticonvulsants | 12 | 2011 | 431 | 0.820 |
Why?
|
Adult | 144 | 2023 | 77950 | 0.810 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 10 | 1994 | 132 | 0.810 |
Why?
|
Yohimbine | 5 | 2013 | 26 | 0.790 |
Why?
|
Neuropsychological Tests | 14 | 2014 | 1178 | 0.790 |
Why?
|
Depressive Disorder, Treatment-Resistant | 4 | 2023 | 92 | 0.750 |
Why?
|
Humans | 221 | 2024 | 261506 | 0.750 |
Why?
|
Psychomotor Agitation | 4 | 2013 | 78 | 0.730 |
Why?
|
Male | 188 | 2024 | 123000 | 0.720 |
Why?
|
Nicotine | 1 | 2021 | 244 | 0.680 |
Why?
|
Double-Blind Method | 39 | 2021 | 2588 | 0.660 |
Why?
|
Lithium Carbonate | 10 | 2017 | 21 | 0.630 |
Why?
|
Electroencephalography | 13 | 2023 | 898 | 0.630 |
Why?
|
Endophenotypes | 3 | 2021 | 18 | 0.610 |
Why?
|
Circadian Rhythm | 12 | 2019 | 330 | 0.610 |
Why?
|
Lurasidone Hydrochloride | 1 | 2017 | 2 | 0.610 |
Why?
|
Irritable Mood | 1 | 2017 | 12 | 0.600 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 10 | 2012 | 231 | 0.600 |
Why?
|
Smoking | 3 | 2022 | 2440 | 0.580 |
Why?
|
Veterans | 3 | 2024 | 1641 | 0.580 |
Why?
|
Prefrontal Cortex | 9 | 2014 | 229 | 0.580 |
Why?
|
Female | 150 | 2023 | 141928 | 0.570 |
Why?
|
Personality Assessment | 10 | 2011 | 105 | 0.560 |
Why?
|
Cocaine | 7 | 2009 | 233 | 0.560 |
Why?
|
Depression | 10 | 2023 | 1715 | 0.550 |
Why?
|
Evidence-Based Medicine | 3 | 2013 | 1085 | 0.550 |
Why?
|
Acoustic Stimulation | 6 | 2016 | 118 | 0.540 |
Why?
|
Evoked Potentials | 5 | 2019 | 190 | 0.540 |
Why?
|
Borderline Personality Disorder | 3 | 2012 | 151 | 0.540 |
Why?
|
Hydrocortisone | 11 | 2013 | 388 | 0.530 |
Why?
|
Rats | 54 | 2010 | 6086 | 0.520 |
Why?
|
Personality Inventory | 8 | 2013 | 178 | 0.520 |
Why?
|
Brain | 21 | 2015 | 4113 | 0.510 |
Why?
|
Serotonin Receptor Agonists | 4 | 2010 | 20 | 0.500 |
Why?
|
Alcohol Drinking | 7 | 2014 | 551 | 0.500 |
Why?
|
Risk-Taking | 2 | 2014 | 133 | 0.480 |
Why?
|
Behavior, Animal | 19 | 2010 | 709 | 0.480 |
Why?
|
Hypothalamo-Hypophyseal System | 7 | 2019 | 127 | 0.470 |
Why?
|
Cognition Disorders | 6 | 2012 | 786 | 0.470 |
Why?
|
Severity of Illness Index | 20 | 2014 | 4320 | 0.460 |
Why?
|
Behavior | 5 | 2009 | 103 | 0.450 |
Why?
|
Comorbidity | 12 | 2017 | 2352 | 0.450 |
Why?
|
Pituitary-Adrenal System | 6 | 2019 | 97 | 0.430 |
Why?
|
Mexican Americans | 2 | 2014 | 322 | 0.430 |
Why?
|
Tryptophan | 4 | 2002 | 127 | 0.430 |
Why?
|
Anxiety Disorders | 9 | 2019 | 666 | 0.430 |
Why?
|
Rats, Sprague-Dawley | 35 | 2010 | 2063 | 0.420 |
Why?
|
Suicidal Ideation | 6 | 2023 | 207 | 0.410 |
Why?
|
Ethanol | 6 | 2010 | 264 | 0.410 |
Why?
|
Catecholamines | 4 | 2013 | 101 | 0.400 |
Why?
|
Middle Aged | 76 | 2021 | 86204 | 0.400 |
Why?
|
Analysis of Variance | 17 | 2013 | 2307 | 0.400 |
Why?
|
Criminals | 1 | 2011 | 15 | 0.390 |
Why?
|
Triazines | 2 | 2009 | 117 | 0.380 |
Why?
|
Patient Compliance | 4 | 2010 | 667 | 0.380 |
Why?
|
Guidelines as Topic | 1 | 2013 | 383 | 0.380 |
Why?
|
Anhedonia | 2 | 2021 | 39 | 0.380 |
Why?
|
Adolescent Behavior | 2 | 2011 | 230 | 0.370 |
Why?
|
Adolescent | 41 | 2023 | 31252 | 0.370 |
Why?
|
Panic | 6 | 1989 | 9 | 0.370 |
Why?
|
Phenylpropanolamine | 1 | 2009 | 4 | 0.360 |
Why?
|
Propylamines | 1 | 2009 | 12 | 0.360 |
Why?
|
Electroconvulsive Therapy | 6 | 2015 | 59 | 0.360 |
Why?
|
Fear | 7 | 2019 | 254 | 0.350 |
Why?
|
Social Behavior | 2 | 2010 | 306 | 0.350 |
Why?
|
Arousal | 7 | 2013 | 120 | 0.350 |
Why?
|
Amphetamine | 7 | 2009 | 19 | 0.350 |
Why?
|
Treatment Outcome | 39 | 2023 | 32848 | 0.340 |
Why?
|
Schizophrenia | 9 | 2024 | 369 | 0.340 |
Why?
|
Cerebral Cortex | 6 | 2019 | 621 | 0.340 |
Why?
|
Methoxyhydroxyphenylglycol | 11 | 1999 | 24 | 0.340 |
Why?
|
Dose-Response Relationship, Drug | 32 | 2011 | 4938 | 0.340 |
Why?
|
Patient Education as Topic | 4 | 2010 | 748 | 0.330 |
Why?
|
Memory | 8 | 2014 | 429 | 0.320 |
Why?
|
Decision Making | 8 | 2010 | 1287 | 0.320 |
Why?
|
Carbamazepine | 7 | 2008 | 49 | 0.320 |
Why?
|
Diagnosis, Differential | 13 | 2019 | 4744 | 0.310 |
Why?
|
Attitude to Health | 1 | 2011 | 465 | 0.300 |
Why?
|
Desipramine | 3 | 1997 | 30 | 0.300 |
Why?
|
Aging | 6 | 2010 | 1582 | 0.300 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 5 | 2022 | 259 | 0.300 |
Why?
|
Life Style | 1 | 2011 | 612 | 0.300 |
Why?
|
Clinical Trials as Topic | 9 | 2013 | 3719 | 0.290 |
Why?
|
Affective Symptoms | 4 | 2014 | 102 | 0.290 |
Why?
|
Stereotyped Behavior | 13 | 2010 | 35 | 0.290 |
Why?
|
Placebos | 13 | 2010 | 437 | 0.290 |
Why?
|
Psychotherapy | 4 | 2019 | 247 | 0.290 |
Why?
|
Psychological Tests | 5 | 2014 | 131 | 0.280 |
Why?
|
Young Adult | 13 | 2020 | 21445 | 0.280 |
Why?
|
Oxazolidinones | 2 | 2010 | 60 | 0.270 |
Why?
|
Drug Therapy, Combination | 10 | 2017 | 2315 | 0.270 |
Why?
|
Risk Factors | 15 | 2023 | 17523 | 0.270 |
Why?
|
Nucleus Accumbens | 4 | 2010 | 61 | 0.270 |
Why?
|
Excitatory Amino Acid Antagonists | 7 | 2015 | 151 | 0.270 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 2005 | 67 | 0.260 |
Why?
|
Alcoholism | 5 | 2014 | 285 | 0.260 |
Why?
|
Dizocilpine Maleate | 6 | 2002 | 21 | 0.260 |
Why?
|
Affective Disorders, Psychotic | 2 | 2000 | 8 | 0.250 |
Why?
|
Cluster Analysis | 4 | 2012 | 1053 | 0.250 |
Why?
|
Psychometrics | 12 | 2023 | 937 | 0.250 |
Why?
|
Emotions | 5 | 2023 | 562 | 0.250 |
Why?
|
Random Allocation | 12 | 2021 | 703 | 0.250 |
Why?
|
Long-Term Care | 1 | 2005 | 83 | 0.250 |
Why?
|
Prolactin | 3 | 2000 | 155 | 0.250 |
Why?
|
Citalopram | 3 | 2009 | 36 | 0.240 |
Why?
|
Event-Related Potentials, P300 | 1 | 2004 | 6 | 0.240 |
Why?
|
Ouabain | 5 | 1991 | 40 | 0.240 |
Why?
|
Adolescent, Hospitalized | 1 | 2003 | 7 | 0.240 |
Why?
|
Drug Interactions | 8 | 2010 | 553 | 0.240 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2021 | 2594 | 0.240 |
Why?
|
N-Methyl-3,4-methylenedioxyamphetamine | 3 | 2009 | 19 | 0.230 |
Why?
|
Hepatitis, Viral, Human | 1 | 2024 | 58 | 0.230 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 1 | 2003 | 41 | 0.230 |
Why?
|
Factor Analysis, Statistical | 4 | 2014 | 356 | 0.230 |
Why?
|
Rats, Inbred Strains | 11 | 1992 | 410 | 0.220 |
Why?
|
Animals | 59 | 2022 | 59536 | 0.220 |
Why?
|
Age of Onset | 4 | 2012 | 827 | 0.220 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 4 | 2009 | 274 | 0.220 |
Why?
|
Dopamine Uptake Inhibitors | 3 | 2008 | 46 | 0.220 |
Why?
|
Auditory Perception | 3 | 2012 | 35 | 0.210 |
Why?
|
Recurrence | 6 | 2013 | 4758 | 0.210 |
Why?
|
Sodium | 4 | 1991 | 353 | 0.210 |
Why?
|
Membrane Transport Modulators | 1 | 2021 | 9 | 0.200 |
Why?
|
Models, Psychological | 3 | 2010 | 170 | 0.200 |
Why?
|
Mood Disorders | 2 | 2002 | 163 | 0.200 |
Why?
|
Sensory Receptor Cells | 1 | 2003 | 141 | 0.200 |
Why?
|
Drug Administration Schedule | 21 | 2009 | 3472 | 0.200 |
Why?
|
Trichotillomania | 4 | 1997 | 32 | 0.200 |
Why?
|
Secondary Prevention | 5 | 2010 | 329 | 0.200 |
Why?
|
KCNQ3 Potassium Channel | 1 | 2021 | 19 | 0.200 |
Why?
|
Ventral Striatum | 1 | 2021 | 19 | 0.200 |
Why?
|
Regression Analysis | 6 | 2013 | 1546 | 0.200 |
Why?
|
Phenylenediamines | 1 | 2021 | 23 | 0.200 |
Why?
|
Life Change Events | 2 | 2013 | 83 | 0.200 |
Why?
|
Drug Tolerance | 7 | 2009 | 114 | 0.190 |
Why?
|
KCNQ2 Potassium Channel | 1 | 2021 | 37 | 0.190 |
Why?
|
Carbamates | 1 | 2021 | 77 | 0.190 |
Why?
|
Dibenzothiazepines | 2 | 2014 | 13 | 0.190 |
Why?
|
Oxazoles | 1 | 2000 | 60 | 0.190 |
Why?
|
Administration, Inhalation | 1 | 2021 | 285 | 0.190 |
Why?
|
Neurosecretory Systems | 1 | 2000 | 66 | 0.180 |
Why?
|
Sympathetic Nervous System | 3 | 1994 | 159 | 0.180 |
Why?
|
Glycols | 4 | 1989 | 8 | 0.180 |
Why?
|
Statistics, Nonparametric | 5 | 2016 | 980 | 0.180 |
Why?
|
History, Medieval | 1 | 2019 | 30 | 0.180 |
Why?
|
History, Ancient | 1 | 2019 | 68 | 0.180 |
Why?
|
Psychopathology | 1 | 2019 | 33 | 0.180 |
Why?
|
Case-Control Studies | 10 | 2014 | 6100 | 0.180 |
Why?
|
History, 18th Century | 1 | 2019 | 89 | 0.180 |
Why?
|
Ventral Tegmental Area | 3 | 2009 | 49 | 0.180 |
Why?
|
Time Factors | 25 | 2011 | 12926 | 0.180 |
Why?
|
Surveys and Questionnaires | 11 | 2014 | 5687 | 0.170 |
Why?
|
Disease Progression | 6 | 2014 | 6682 | 0.170 |
Why?
|
Psychomotor Disorders | 1 | 1999 | 32 | 0.170 |
Why?
|
History, 19th Century | 1 | 2019 | 154 | 0.170 |
Why?
|
Social Environment | 2 | 2011 | 176 | 0.170 |
Why?
|
Personality Disorders | 3 | 2015 | 164 | 0.170 |
Why?
|
Droperidol | 1 | 1998 | 3 | 0.170 |
Why?
|
Facial Expression | 1 | 2019 | 49 | 0.170 |
Why?
|
Oxidopamine | 5 | 2009 | 15 | 0.170 |
Why?
|
Ambulatory Care | 7 | 2003 | 554 | 0.170 |
Why?
|
Body Temperature | 3 | 2000 | 158 | 0.170 |
Why?
|
Neuroprotective Agents | 1 | 2020 | 215 | 0.160 |
Why?
|
Clonidine | 3 | 1993 | 71 | 0.160 |
Why?
|
Hydroxyindoleacetic Acid | 6 | 1994 | 25 | 0.160 |
Why?
|
gamma-Aminobutyric Acid | 1 | 1999 | 269 | 0.160 |
Why?
|
Diagnosis, Dual (Psychiatry) | 4 | 2014 | 23 | 0.160 |
Why?
|
Hallucinogens | 3 | 2009 | 48 | 0.160 |
Why?
|
Phenelzine | 1 | 1997 | 4 | 0.150 |
Why?
|
Monoamine Oxidase Inhibitors | 1 | 1997 | 19 | 0.150 |
Why?
|
Physostigmine | 2 | 1988 | 8 | 0.150 |
Why?
|
Menstrual Cycle | 1 | 1997 | 56 | 0.150 |
Why?
|
Clozapine | 2 | 2015 | 24 | 0.150 |
Why?
|
Placebo Effect | 3 | 2013 | 39 | 0.150 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 1997 | 35 | 0.150 |
Why?
|
Multivariate Analysis | 5 | 2013 | 4298 | 0.150 |
Why?
|
History, 20th Century | 1 | 2019 | 574 | 0.150 |
Why?
|
Psychoacoustics | 1 | 2016 | 5 | 0.150 |
Why?
|
Locomotion | 3 | 2009 | 84 | 0.150 |
Why?
|
Blood Pressure | 3 | 2013 | 1467 | 0.150 |
Why?
|
Exercise | 1 | 2004 | 1183 | 0.150 |
Why?
|
Psychotic Disorders | 5 | 2014 | 147 | 0.140 |
Why?
|
Hospitalization | 14 | 2014 | 2083 | 0.140 |
Why?
|
Caudate Nucleus | 2 | 2007 | 43 | 0.140 |
Why?
|
Tryptamines | 2 | 2010 | 8 | 0.140 |
Why?
|
Psychotropic Drugs | 6 | 2010 | 133 | 0.140 |
Why?
|
Imipramine | 5 | 1994 | 29 | 0.140 |
Why?
|
Bayes Theorem | 5 | 2021 | 1021 | 0.140 |
Why?
|
Psychomotor Performance | 2 | 2009 | 233 | 0.140 |
Why?
|
Homovanillic Acid | 5 | 1994 | 21 | 0.130 |
Why?
|
Conduct Disorder | 2 | 2007 | 26 | 0.130 |
Why?
|
Colforsin | 3 | 1992 | 59 | 0.130 |
Why?
|
Texas | 15 | 2014 | 6311 | 0.130 |
Why?
|
Adrenal Medulla | 2 | 1994 | 17 | 0.130 |
Why?
|
Sex Factors | 9 | 2014 | 2139 | 0.130 |
Why?
|
Acute Disease | 8 | 2008 | 2422 | 0.130 |
Why?
|
Nortriptyline | 1 | 1995 | 5 | 0.130 |
Why?
|
Substance Withdrawal Syndrome | 2 | 1997 | 242 | 0.130 |
Why?
|
Self-Control | 1 | 2015 | 20 | 0.130 |
Why?
|
Rubidium | 2 | 1994 | 10 | 0.130 |
Why?
|
Social Perception | 1 | 1995 | 76 | 0.130 |
Why?
|
Infusions, Intravenous | 3 | 2022 | 1382 | 0.130 |
Why?
|
Biogenic Amines | 1 | 1994 | 15 | 0.130 |
Why?
|
Interview, Psychological | 3 | 2014 | 98 | 0.130 |
Why?
|
Cations | 1 | 1994 | 62 | 0.120 |
Why?
|
Dopamine | 4 | 2009 | 312 | 0.120 |
Why?
|
Alzheimer Disease | 4 | 2005 | 855 | 0.120 |
Why?
|
Diffusion Magnetic Resonance Imaging | 2 | 2007 | 341 | 0.120 |
Why?
|
Rats, Inbred WKY | 7 | 2009 | 110 | 0.120 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2021 | 604 | 0.120 |
Why?
|
Education | 1 | 2014 | 112 | 0.120 |
Why?
|
Statistics as Topic | 3 | 2012 | 445 | 0.120 |
Why?
|
Risk Reduction Behavior | 1 | 2015 | 227 | 0.120 |
Why?
|
Age Factors | 8 | 2014 | 5377 | 0.120 |
Why?
|
Gonadotropins | 1 | 2013 | 50 | 0.120 |
Why?
|
Brain Mapping | 4 | 2014 | 644 | 0.120 |
Why?
|
Personality | 1 | 2015 | 116 | 0.120 |
Why?
|
Bupropion | 1 | 1994 | 76 | 0.120 |
Why?
|
Membrane Fluidity | 2 | 1990 | 22 | 0.120 |
Why?
|
Delusions | 2 | 2004 | 21 | 0.120 |
Why?
|
Psychological Theory | 1 | 2013 | 47 | 0.110 |
Why?
|
Cyclothymic Disorder | 1 | 2013 | 3 | 0.110 |
Why?
|
Epilepsy, Complex Partial | 1 | 1993 | 18 | 0.110 |
Why?
|
Pirenzepine | 2 | 2003 | 9 | 0.110 |
Why?
|
Ion Channels | 1 | 1994 | 212 | 0.110 |
Why?
|
Basal Ganglia Diseases | 1 | 1993 | 29 | 0.110 |
Why?
|
Adult Survivors of Child Abuse | 1 | 2013 | 17 | 0.110 |
Why?
|
Catatonia | 1 | 1993 | 12 | 0.110 |
Why?
|
Dexamethasone | 5 | 1994 | 1450 | 0.110 |
Why?
|
Temporal Lobe | 3 | 2000 | 192 | 0.110 |
Why?
|
Cognition | 2 | 2010 | 968 | 0.110 |
Why?
|
Discrimination Learning | 2 | 2008 | 30 | 0.110 |
Why?
|
Testosterone | 1 | 1997 | 619 | 0.110 |
Why?
|
Frontal Lobe | 2 | 2006 | 187 | 0.110 |
Why?
|
Child | 9 | 2023 | 29154 | 0.110 |
Why?
|
Social Support | 1 | 1995 | 560 | 0.110 |
Why?
|
Genotype | 3 | 2022 | 4109 | 0.110 |
Why?
|
Behavior Therapy | 2 | 2007 | 298 | 0.100 |
Why?
|
Receptors, Adrenergic | 1 | 1992 | 46 | 0.100 |
Why?
|
Biomarkers | 2 | 2023 | 5047 | 0.100 |
Why?
|
GABA Uptake Inhibitors | 1 | 2011 | 2 | 0.100 |
Why?
|
Saliva | 1 | 2013 | 231 | 0.100 |
Why?
|
Nipecotic Acids | 1 | 2011 | 8 | 0.100 |
Why?
|
Aged | 33 | 2024 | 70117 | 0.100 |
Why?
|
Receptors, Adrenergic, alpha | 2 | 1989 | 15 | 0.100 |
Why?
|
Canada | 1 | 2013 | 429 | 0.100 |
Why?
|
Triiodothyronine | 2 | 1989 | 77 | 0.100 |
Why?
|
Drug Resistance | 3 | 2009 | 587 | 0.100 |
Why?
|
Erythrocytes | 3 | 1990 | 339 | 0.100 |
Why?
|
Agoraphobia | 2 | 1987 | 7 | 0.100 |
Why?
|
Tetrodotoxin | 1 | 1991 | 68 | 0.100 |
Why?
|
Receptors, Adrenergic, beta | 2 | 1989 | 97 | 0.100 |
Why?
|
Delayed-Action Preparations | 5 | 2014 | 208 | 0.100 |
Why?
|
Euphoria | 2 | 2002 | 9 | 0.100 |
Why?
|
Diagnostic Errors | 3 | 2013 | 509 | 0.100 |
Why?
|
Amitriptyline | 5 | 1997 | 38 | 0.100 |
Why?
|
Phobic Disorders | 2 | 1987 | 43 | 0.100 |
Why?
|
Corpus Callosum | 3 | 2007 | 138 | 0.100 |
Why?
|
Environment | 1 | 1992 | 190 | 0.100 |
Why?
|
Patient Dropouts | 4 | 2011 | 88 | 0.090 |
Why?
|
Fluorides | 1 | 1990 | 25 | 0.090 |
Why?
|
Adrenal Cortex | 1 | 1990 | 35 | 0.090 |
Why?
|
Atomoxetine Hydrochloride | 1 | 2009 | 16 | 0.090 |
Why?
|
Behavioral Research | 1 | 2010 | 23 | 0.090 |
Why?
|
Combined Modality Therapy | 4 | 2005 | 8865 | 0.090 |
Why?
|
Adrenergic Agents | 1 | 2009 | 18 | 0.090 |
Why?
|
Interpersonal Relations | 2 | 2003 | 290 | 0.090 |
Why?
|
Rhinitis, Allergic, Seasonal | 1 | 2009 | 26 | 0.090 |
Why?
|
Peer Group | 1 | 2011 | 133 | 0.090 |
Why?
|
Heart Rate | 1 | 2013 | 737 | 0.090 |
Why?
|
Stress, Physiological | 2 | 2005 | 492 | 0.090 |
Why?
|
Auditory Pathways | 1 | 2009 | 18 | 0.090 |
Why?
|
Sensation | 1 | 2009 | 71 | 0.090 |
Why?
|
Magnetic Resonance Imaging | 6 | 2023 | 7702 | 0.090 |
Why?
|
Avoidance Learning | 1 | 1989 | 94 | 0.090 |
Why?
|
Naltrexone | 1 | 2009 | 87 | 0.090 |
Why?
|
Parent-Child Relations | 1 | 2011 | 257 | 0.080 |
Why?
|
Amphetamine-Related Disorders | 2 | 2007 | 50 | 0.080 |
Why?
|
Hemicholinium 3 | 1 | 1988 | 4 | 0.080 |
Why?
|
Practice Guidelines as Topic | 4 | 2005 | 2403 | 0.080 |
Why?
|
Parasympathetic Nervous System | 1 | 1988 | 26 | 0.080 |
Why?
|
Narcotic Antagonists | 1 | 2009 | 129 | 0.080 |
Why?
|
Adrenal Glands | 1 | 1988 | 122 | 0.080 |
Why?
|
Medical Records | 1 | 2010 | 415 | 0.080 |
Why?
|
Task Performance and Analysis | 1 | 2008 | 136 | 0.080 |
Why?
|
Obsessive-Compulsive Disorder | 2 | 1993 | 622 | 0.080 |
Why?
|
Data Collection | 2 | 2009 | 620 | 0.080 |
Why?
|
Residence Characteristics | 1 | 2011 | 348 | 0.080 |
Why?
|
Choline | 1 | 1988 | 76 | 0.080 |
Why?
|
Follow-Up Studies | 10 | 2013 | 14889 | 0.080 |
Why?
|
Research Design | 5 | 2006 | 1544 | 0.080 |
Why?
|
Hostility | 2 | 2002 | 24 | 0.080 |
Why?
|
Retrospective Studies | 6 | 2022 | 37905 | 0.080 |
Why?
|
Algorithms | 4 | 2005 | 3890 | 0.080 |
Why?
|
Glutamic Acid | 1 | 2009 | 309 | 0.080 |
Why?
|
Hospitals, Psychiatric | 3 | 2003 | 82 | 0.080 |
Why?
|
Dementia | 2 | 2004 | 453 | 0.080 |
Why?
|
Myocardium | 3 | 1989 | 1313 | 0.080 |
Why?
|
Violence | 4 | 2013 | 116 | 0.080 |
Why?
|
Token Economy | 1 | 2007 | 5 | 0.080 |
Why?
|
Serotonin | 4 | 2000 | 264 | 0.070 |
Why?
|
Thyroid Gland | 1 | 1989 | 355 | 0.070 |
Why?
|
Physician-Patient Relations | 1 | 2013 | 792 | 0.070 |
Why?
|
Parents | 1 | 2014 | 998 | 0.070 |
Why?
|
Motivation | 2 | 2007 | 499 | 0.070 |
Why?
|
Pilot Projects | 3 | 2009 | 2803 | 0.070 |
Why?
|
Demyelinating Diseases | 1 | 2007 | 77 | 0.070 |
Why?
|
Brain Chemistry | 3 | 2009 | 145 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2011 | 1945 | 0.070 |
Why?
|
Synaptic Transmission | 1 | 2009 | 443 | 0.070 |
Why?
|
Reference Values | 3 | 2005 | 1099 | 0.070 |
Why?
|
Hyperkinesis | 2 | 2006 | 23 | 0.070 |
Why?
|
Potassium | 3 | 1994 | 329 | 0.070 |
Why?
|
Evoked Potentials, Somatosensory | 1 | 2006 | 60 | 0.070 |
Why?
|
Myelin Sheath | 1 | 2007 | 149 | 0.070 |
Why?
|
Cross-Sectional Studies | 3 | 2007 | 4314 | 0.070 |
Why?
|
Memory Disorders | 2 | 2004 | 295 | 0.070 |
Why?
|
Tail | 1 | 2005 | 28 | 0.070 |
Why?
|
Pyrimidines | 1 | 1998 | 3518 | 0.070 |
Why?
|
Epinephrine | 4 | 1994 | 255 | 0.070 |
Why?
|
Rats, Inbred SHR | 4 | 2009 | 113 | 0.070 |
Why?
|
Hydroxydopamines | 3 | 1989 | 5 | 0.070 |
Why?
|
Urban Population | 1 | 2007 | 269 | 0.070 |
Why?
|
Health Status | 2 | 2006 | 590 | 0.070 |
Why?
|
Adaptation, Psychological | 1 | 1990 | 764 | 0.070 |
Why?
|
Prevalence | 3 | 2014 | 3260 | 0.070 |
Why?
|
Regional Blood Flow | 1 | 2006 | 276 | 0.060 |
Why?
|
Phenylcarbamates | 1 | 2005 | 25 | 0.060 |
Why?
|
Medical History Taking | 1 | 2005 | 173 | 0.060 |
Why?
|
Schizophrenic Psychology | 3 | 1995 | 102 | 0.060 |
Why?
|
Family | 2 | 2001 | 736 | 0.060 |
Why?
|
Risk | 1 | 2009 | 1972 | 0.060 |
Why?
|
Hallucinations | 1 | 2004 | 35 | 0.060 |
Why?
|
Feeding Behavior | 2 | 1989 | 808 | 0.060 |
Why?
|
Brief Psychiatric Rating Scale | 2 | 2001 | 9 | 0.060 |
Why?
|
Cholinesterase Inhibitors | 1 | 2005 | 110 | 0.060 |
Why?
|
Central Nervous System | 1 | 2006 | 436 | 0.060 |
Why?
|
Calcium | 1 | 1990 | 1537 | 0.060 |
Why?
|
Intelligence Tests | 1 | 2003 | 88 | 0.060 |
Why?
|
Cell Membrane | 1 | 1987 | 850 | 0.060 |
Why?
|
Wounds, Gunshot | 1 | 1985 | 102 | 0.060 |
Why?
|
Administration, Oral | 3 | 1998 | 1544 | 0.060 |
Why?
|
Models, Statistical | 1 | 2010 | 1171 | 0.060 |
Why?
|
Phenylacetates | 1 | 1983 | 20 | 0.060 |
Why?
|
Serotonin Agents | 1 | 2003 | 16 | 0.060 |
Why?
|
Inpatients | 2 | 2022 | 678 | 0.060 |
Why?
|
Disease Susceptibility | 1 | 2006 | 538 | 0.060 |
Why?
|
Kinetics | 3 | 2000 | 2049 | 0.060 |
Why?
|
Interviews as Topic | 1 | 2004 | 497 | 0.060 |
Why?
|
Biological Transport, Active | 2 | 1994 | 131 | 0.050 |
Why?
|
Benzodiazepines | 4 | 2008 | 170 | 0.050 |
Why?
|
Lithium Compounds | 2 | 2015 | 15 | 0.050 |
Why?
|
Sampling Studies | 1 | 2002 | 170 | 0.050 |
Why?
|
Receptors, Serotonin | 1 | 2002 | 46 | 0.050 |
Why?
|
Antidepressive Agents, Second-Generation | 2 | 2004 | 56 | 0.050 |
Why?
|
Reproducibility of Results | 5 | 2015 | 6009 | 0.050 |
Why?
|
Movement | 1 | 2005 | 556 | 0.050 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 1 | 2022 | 51 | 0.050 |
Why?
|
Tobacco Use | 1 | 2022 | 54 | 0.050 |
Why?
|
Injections, Intraventricular | 3 | 1991 | 114 | 0.050 |
Why?
|
Imitative Behavior | 1 | 2001 | 11 | 0.050 |
Why?
|
Phenethylamines | 1 | 2021 | 14 | 0.050 |
Why?
|
Photoperiod | 2 | 2004 | 31 | 0.050 |
Why?
|
Logistic Models | 3 | 2004 | 3441 | 0.050 |
Why?
|
Mental Health Services | 2 | 2002 | 227 | 0.050 |
Why?
|
Excitatory Amino Acids | 1 | 2001 | 8 | 0.050 |
Why?
|
Dementia, Vascular | 1 | 2001 | 16 | 0.050 |
Why?
|
Psychology, Adolescent | 1 | 2001 | 41 | 0.050 |
Why?
|
Mass Media | 1 | 2001 | 36 | 0.050 |
Why?
|
Residential Facilities | 1 | 2001 | 5 | 0.050 |
Why?
|
Lewy Body Disease | 1 | 2001 | 20 | 0.050 |
Why?
|
Functional Neuroimaging | 1 | 2021 | 38 | 0.050 |
Why?
|
Rubidium Radioisotopes | 2 | 1991 | 6 | 0.050 |
Why?
|
Terminology as Topic | 2 | 1995 | 414 | 0.050 |
Why?
|
Monensin | 2 | 1991 | 8 | 0.050 |
Why?
|
Vanilmandelic Acid | 3 | 1991 | 10 | 0.050 |
Why?
|
Homes for the Aged | 1 | 2001 | 24 | 0.050 |
Why?
|
Quinolinic Acid | 1 | 2020 | 23 | 0.050 |
Why?
|
Kynurenic Acid | 1 | 2020 | 26 | 0.050 |
Why?
|
Prognosis | 7 | 2013 | 21713 | 0.050 |
Why?
|
Puerperal Disorders | 1 | 2001 | 41 | 0.050 |
Why?
|
Population Dynamics | 1 | 2001 | 42 | 0.050 |
Why?
|
Phenylephrine | 2 | 1992 | 48 | 0.050 |
Why?
|
Quetiapine Fumarate | 2 | 2014 | 16 | 0.050 |
Why?
|
GABA Agonists | 1 | 2000 | 23 | 0.050 |
Why?
|
Isoproterenol | 2 | 1992 | 127 | 0.050 |
Why?
|
Kynurenine | 1 | 2020 | 71 | 0.050 |
Why?
|
Models, Economic | 1 | 2001 | 101 | 0.050 |
Why?
|
Endocrine System Diseases | 1 | 2001 | 83 | 0.050 |
Why?
|
Neurotransmitter Agents | 2 | 1994 | 159 | 0.050 |
Why?
|
Dominance, Cerebral | 1 | 2000 | 81 | 0.050 |
Why?
|
Amygdala | 1 | 2021 | 127 | 0.050 |
Why?
|
Food Deprivation | 1 | 2000 | 47 | 0.050 |
Why?
|
Apolipoproteins E | 1 | 2001 | 221 | 0.050 |
Why?
|
Nursing Homes | 1 | 2001 | 99 | 0.050 |
Why?
|
Human Growth Hormone | 1 | 2000 | 82 | 0.050 |
Why?
|
Androgen Antagonists | 1 | 2003 | 411 | 0.050 |
Why?
|
Pregnancy | 2 | 2005 | 7573 | 0.040 |
Why?
|
Polymorphism, Genetic | 2 | 2022 | 1450 | 0.040 |
Why?
|
Drug Hypersensitivity | 1 | 2001 | 128 | 0.040 |
Why?
|
Happiness | 1 | 2019 | 11 | 0.040 |
Why?
|
Reinforcement Schedule | 1 | 1999 | 26 | 0.040 |
Why?
|
Personality Tests | 1 | 1999 | 18 | 0.040 |
Why?
|
Buspirone | 1 | 1999 | 7 | 0.040 |
Why?
|
Risk Assessment | 2 | 2011 | 6869 | 0.040 |
Why?
|
Species Specificity | 3 | 2006 | 777 | 0.040 |
Why?
|
Methimazole | 2 | 1989 | 6 | 0.040 |
Why?
|
Behavior, Addictive | 1 | 2000 | 99 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2020 | 460 | 0.040 |
Why?
|
Neural Pathways | 3 | 2009 | 298 | 0.040 |
Why?
|
Breast Feeding | 1 | 2001 | 239 | 0.040 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 2001 | 193 | 0.040 |
Why?
|
Environmental Exposure | 1 | 2001 | 288 | 0.040 |
Why?
|
Eye Movements | 1 | 1999 | 116 | 0.040 |
Why?
|
Chi-Square Distribution | 4 | 2003 | 1323 | 0.040 |
Why?
|
Neurons | 1 | 2009 | 2287 | 0.040 |
Why?
|
Mice | 1 | 2019 | 34495 | 0.040 |
Why?
|
Exanthema | 1 | 2001 | 211 | 0.040 |
Why?
|
Dietary Proteins | 1 | 2000 | 241 | 0.040 |
Why?
|
Ritanserin | 1 | 1997 | 3 | 0.040 |
Why?
|
Gender Identity | 2 | 1995 | 75 | 0.040 |
Why?
|
Gambling | 2 | 2009 | 22 | 0.040 |
Why?
|
Serotonin Antagonists | 1 | 1997 | 41 | 0.040 |
Why?
|
Decision Trees | 3 | 2005 | 178 | 0.040 |
Why?
|
Fluvoxamine | 1 | 1997 | 6 | 0.040 |
Why?
|
Trauma Severity Indices | 1 | 1998 | 98 | 0.040 |
Why?
|
Follicular Phase | 1 | 1997 | 16 | 0.040 |
Why?
|
Cohort Studies | 4 | 2024 | 9244 | 0.040 |
Why?
|
Panic Disorder | 1 | 1997 | 46 | 0.040 |
Why?
|
Menstruation | 1 | 1997 | 39 | 0.040 |
Why?
|
Weight Gain | 1 | 2001 | 464 | 0.040 |
Why?
|
Mathematical Computing | 1 | 1997 | 22 | 0.040 |
Why?
|
Self-Injurious Behavior | 1 | 1998 | 54 | 0.040 |
Why?
|
Fetal Diseases | 1 | 2001 | 388 | 0.040 |
Why?
|
Body Weight | 4 | 2006 | 1293 | 0.040 |
Why?
|
Ovulation | 1 | 1997 | 107 | 0.040 |
Why?
|
Socioeconomic Factors | 3 | 1996 | 1225 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2004 | 4892 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 1997 | 276 | 0.030 |
Why?
|
Pregnancy Complications | 1 | 2001 | 526 | 0.030 |
Why?
|
Enzyme Activation | 2 | 1990 | 1764 | 0.030 |
Why?
|
Community Mental Health Services | 1 | 1995 | 38 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2003 | 1879 | 0.030 |
Why?
|
Delay Discounting | 1 | 2015 | 8 | 0.030 |
Why?
|
Length of Stay | 2 | 2000 | 1900 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2024 | 2265 | 0.030 |
Why?
|
Quality of Life | 4 | 2004 | 4532 | 0.030 |
Why?
|
United States | 2 | 2011 | 15433 | 0.030 |
Why?
|
Stress, Psychological | 1 | 2001 | 1000 | 0.030 |
Why?
|
Social Adjustment | 2 | 2001 | 114 | 0.030 |
Why?
|
Substance Abuse Detection | 2 | 2007 | 64 | 0.030 |
Why?
|
Pyridines | 1 | 2021 | 1244 | 0.030 |
Why?
|
Confusion | 1 | 2014 | 31 | 0.030 |
Why?
|
Gray Matter | 1 | 2014 | 63 | 0.030 |
Why?
|
Craving | 1 | 2014 | 42 | 0.030 |
Why?
|
Nonverbal Communication | 1 | 1993 | 9 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 1999 | 4971 | 0.030 |
Why?
|
Appointments and Schedules | 1 | 1993 | 98 | 0.030 |
Why?
|
Organ Size | 1 | 2014 | 690 | 0.030 |
Why?
|
Survival Analysis | 4 | 2009 | 9180 | 0.030 |
Why?
|
Exploratory Behavior | 2 | 2006 | 106 | 0.030 |
Why?
|
Odds Ratio | 4 | 2001 | 2316 | 0.030 |
Why?
|
Alprazolam | 2 | 1989 | 8 | 0.030 |
Why?
|
Drug Synergism | 2 | 2010 | 1313 | 0.030 |
Why?
|
Temperament | 1 | 2012 | 21 | 0.030 |
Why?
|
Prosencephalon | 1 | 1992 | 43 | 0.030 |
Why?
|
Dopamine beta-Hydroxylase | 1 | 1992 | 38 | 0.030 |
Why?
|
Adenylyl Cyclases | 1 | 1992 | 87 | 0.030 |
Why?
|
Family Health | 1 | 2013 | 325 | 0.030 |
Why?
|
Fluoxetine | 1 | 1991 | 43 | 0.030 |
Why?
|
Observer Variation | 1 | 1993 | 671 | 0.020 |
Why?
|
Calcimycin | 1 | 1990 | 48 | 0.020 |
Why?
|
Microsomes | 1 | 1990 | 61 | 0.020 |
Why?
|
Diet | 1 | 1999 | 1440 | 0.020 |
Why?
|
Synaptosomes | 1 | 1990 | 37 | 0.020 |
Why?
|
Dimethyl Sulfoxide | 1 | 1990 | 52 | 0.020 |
Why?
|
4-Nitrophenylphosphatase | 1 | 1989 | 3 | 0.020 |
Why?
|
Membranes | 1 | 1989 | 31 | 0.020 |
Why?
|
Ibotenic Acid | 1 | 2009 | 4 | 0.020 |
Why?
|
Metabolic Clearance Rate | 1 | 1990 | 231 | 0.020 |
Why?
|
Running | 1 | 2010 | 46 | 0.020 |
Why?
|
Locus Coeruleus | 1 | 1989 | 33 | 0.020 |
Why?
|
Extinction, Psychological | 1 | 1989 | 31 | 0.020 |
Why?
|
Breath Tests | 1 | 2010 | 177 | 0.020 |
Why?
|
Sensation Disorders | 1 | 2009 | 27 | 0.020 |
Why?
|
Prospective Studies | 4 | 2013 | 12873 | 0.020 |
Why?
|
Hunger | 1 | 1989 | 47 | 0.020 |
Why?
|
Orientation | 1 | 1989 | 57 | 0.020 |
Why?
|
Lymphocytes | 1 | 1994 | 1234 | 0.020 |
Why?
|
Aged, 80 and over | 3 | 2004 | 29902 | 0.020 |
Why?
|
Propranolol | 1 | 1989 | 156 | 0.020 |
Why?
|
Self Report | 1 | 2013 | 756 | 0.020 |
Why?
|
Electrodes, Implanted | 1 | 2009 | 183 | 0.020 |
Why?
|
Muscles | 1 | 1990 | 416 | 0.020 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 1990 | 243 | 0.020 |
Why?
|
Reserpine | 1 | 1988 | 10 | 0.020 |
Why?
|
Adenosine Triphosphate | 1 | 1990 | 571 | 0.020 |
Why?
|
Dihydroalprenolol | 1 | 1988 | 2 | 0.020 |
Why?
|
Receptors, Muscarinic | 1 | 1988 | 69 | 0.020 |
Why?
|
Automobile Driving | 1 | 1987 | 29 | 0.020 |
Why?
|
Adrenalectomy | 1 | 1988 | 188 | 0.020 |
Why?
|
Darkness | 2 | 1998 | 28 | 0.020 |
Why?
|
Metanephrine | 1 | 1987 | 6 | 0.020 |
Why?
|
Perception | 1 | 2009 | 350 | 0.020 |
Why?
|
Sensory Thresholds | 1 | 2007 | 68 | 0.020 |
Why?
|
Catheterization | 1 | 2009 | 410 | 0.020 |
Why?
|
Employment | 1 | 1987 | 129 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 1989 | 1618 | 0.020 |
Why?
|
Anisotropy | 1 | 2007 | 181 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 1987 | 306 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2007 | 218 | 0.020 |
Why?
|
Cell Line | 1 | 1994 | 5114 | 0.020 |
Why?
|
Light | 2 | 1998 | 245 | 0.020 |
Why?
|
Time | 1 | 2006 | 178 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2008 | 482 | 0.020 |
Why?
|
Bias | 2 | 1998 | 205 | 0.020 |
Why?
|
Specimen Handling | 1 | 1988 | 299 | 0.020 |
Why?
|
Capsules | 1 | 2006 | 53 | 0.020 |
Why?
|
Hypothyroidism | 1 | 1988 | 204 | 0.020 |
Why?
|
Health Care Costs | 2 | 2003 | 674 | 0.020 |
Why?
|
Epilepsy, Temporal Lobe | 1 | 1986 | 101 | 0.020 |
Why?
|
Rest | 1 | 2005 | 71 | 0.020 |
Why?
|
Ligands | 1 | 1988 | 995 | 0.020 |
Why?
|
Drug Evaluation | 1 | 2005 | 425 | 0.020 |
Why?
|
Rivastigmine | 1 | 2005 | 26 | 0.020 |
Why?
|
Wakefulness | 1 | 2006 | 150 | 0.020 |
Why?
|
Dizziness | 1 | 2005 | 47 | 0.020 |
Why?
|
Feasibility Studies | 2 | 2001 | 2292 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2009 | 7222 | 0.020 |
Why?
|
Paroxetine | 1 | 2004 | 34 | 0.020 |
Why?
|
Trauma Centers | 1 | 1985 | 163 | 0.010 |
Why?
|
Self-Assessment | 1 | 2004 | 96 | 0.010 |
Why?
|
Injections, Intraperitoneal | 1 | 2003 | 197 | 0.010 |
Why?
|
Hippocampus | 1 | 1989 | 915 | 0.010 |
Why?
|
Ataxia | 1 | 2005 | 176 | 0.010 |
Why?
|
Water | 1 | 2005 | 361 | 0.010 |
Why?
|
Patient Care Planning | 1 | 2005 | 297 | 0.010 |
Why?
|
Nausea | 1 | 2005 | 525 | 0.010 |
Why?
|
Withholding Treatment | 1 | 2004 | 161 | 0.010 |
Why?
|
Magnesium | 1 | 1983 | 160 | 0.010 |
Why?
|
Receptor, Serotonin, 5-HT2A | 1 | 2002 | 13 | 0.010 |
Why?
|
Health Services | 1 | 2003 | 105 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2014 | 4549 | 0.010 |
Why?
|
Cells, Cultured | 1 | 1990 | 5637 | 0.010 |
Why?
|
Community Mental Health Centers | 1 | 2001 | 9 | 0.010 |
Why?
|
Treatment Failure | 1 | 2005 | 1391 | 0.010 |
Why?
|
GABA Agents | 1 | 2001 | 26 | 0.010 |
Why?
|
Sleep Wake Disorders | 1 | 2005 | 348 | 0.010 |
Why?
|
Urban Health | 1 | 2001 | 75 | 0.010 |
Why?
|
Language Disorders | 1 | 2001 | 26 | 0.010 |
Why?
|
Direct Service Costs | 1 | 2001 | 12 | 0.010 |
Why?
|
Drug Antagonism | 1 | 2001 | 32 | 0.010 |
Why?
|
Apolipoprotein E4 | 1 | 2001 | 48 | 0.010 |
Why?
|
Consensus | 1 | 2005 | 978 | 0.010 |
Why?
|
Heart | 1 | 1988 | 1223 | 0.010 |
Why?
|
Obesity | 1 | 2013 | 2884 | 0.010 |
Why?
|
Psychiatric Nursing | 1 | 2000 | 6 | 0.010 |
Why?
|
Perceptual Masking | 1 | 2000 | 6 | 0.010 |
Why?
|
Clinical Laboratory Techniques | 1 | 2002 | 203 | 0.010 |
Why?
|
United Kingdom | 1 | 2001 | 257 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 2005 | 585 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2014 | 5539 | 0.010 |
Why?
|
Anti-Anxiety Agents | 1 | 2001 | 90 | 0.010 |
Why?
|
Consensus Development Conferences as Topic | 1 | 1999 | 75 | 0.010 |
Why?
|
Morphine | 1 | 2000 | 308 | 0.010 |
Why?
|
Genetic Markers | 1 | 2001 | 974 | 0.010 |
Why?
|
Drug Combinations | 1 | 2000 | 621 | 0.010 |
Why?
|
Genetic Variation | 1 | 2006 | 2086 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2001 | 552 | 0.010 |
Why?
|
Drug Costs | 1 | 1999 | 144 | 0.010 |
Why?
|
Population Surveillance | 1 | 2001 | 627 | 0.010 |
Why?
|
Preventive Health Services | 1 | 1998 | 75 | 0.010 |
Why?
|
Clinical Protocols | 1 | 1999 | 467 | 0.010 |
Why?
|
Corpus Striatum | 1 | 1997 | 104 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2001 | 636 | 0.010 |
Why?
|
Injections, Subcutaneous | 1 | 1996 | 334 | 0.010 |
Why?
|
Patient Discharge | 1 | 2000 | 661 | 0.010 |
Why?
|
Physician's Role | 1 | 1998 | 238 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 1999 | 945 | 0.010 |
Why?
|
Tissue Distribution | 1 | 1996 | 875 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2001 | 918 | 0.010 |
Why?
|
Syndrome | 1 | 1997 | 1351 | 0.010 |
Why?
|
DNA | 1 | 2002 | 2693 | 0.010 |
Why?
|
Chronic Disease | 1 | 1999 | 1819 | 0.010 |
Why?
|
Models, Biological | 2 | 1996 | 3254 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2001 | 1148 | 0.010 |
Why?
|
Video Recording | 1 | 1993 | 267 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2000 | 1371 | 0.010 |
Why?
|
Incidence | 1 | 2001 | 5673 | 0.010 |
Why?
|
Patient Selection | 1 | 1997 | 2055 | 0.010 |
Why?
|
Patient Care Team | 1 | 1993 | 795 | 0.000 |
Why?
|
Liver | 1 | 1997 | 2961 | 0.000 |
Why?
|
Remission Induction | 1 | 1993 | 3569 | 0.000 |
Why?
|
Normetanephrine | 1 | 1986 | 4 | 0.000 |
Why?
|
Feeding and Eating Disorders | 1 | 1987 | 97 | 0.000 |
Why?
|
Sleep | 1 | 1989 | 413 | 0.000 |
Why?
|
Menopause | 1 | 1986 | 159 | 0.000 |
Why?
|
Infant | 1 | 2001 | 13310 | 0.000 |
Why?
|
Child, Preschool | 1 | 2001 | 16273 | 0.000 |
Why?
|